Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I, Multi-Centre, Randomised, Placebo-Controlled, Dose Escalation Study to Assess Local & Systemic Tolerability of Therapeutic DNA Plasmid pdpSC18 Vaccine Administered by Particle Mediated Epidermal Delivery Using PowderJect ND10 Delivery System in Subjects With Chronic Hepatitis B Infection

NCT00277576 is registered in ClinicalTrials.gov with PowderMed as lead sponsor.

NCT NCT00277576
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00277576 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I, Multi-Centre, Randomised, Placebo-Controlled, Dose Escalation Study to Assess Local & Systemic Tolerability of Therapeutic DNA Plasmid pdpSC18 Vaccine Administered by Particle Mediated Epidermal Delivery Using PowderJect ND10 Delivery System in Subjects With Chronic Hepatitis B Infection
Lead sponsor
PowderMed
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2006
Completion date
December 31, 2007
Enrollment
48 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis b